SAMANTHA WORKS: Open Payments
NPI 1962884916 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,902 in 274 payments from 19 companies in 2025. Trend: 2023 $667 · 2024 $2,632 · 2025 $4,902
Food & beverage: $4,902
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 52 | $898 |
| Teva Pharmaceuticals USA, Inc. | 40 | $793 |
| Neurocrine BioSciences, Inc. | 38 | $530 |
| E.R. Squibb & Sons, L.L.C. | 29 | $427 |
| Vanda Pharmaceuticals Inc. | 16 | $420 |
| Alkermes, Inc. | 24 | $410 |
| ABBVIE INC. | 22 | $405 |
| Otsuka America Pharmaceutical, Inc. | 22 | $393 |
| Collegium Pharmaceutical, Inc. | 6 | $116 |
| Biogen, Inc. | 5 | $112 |
Products named: CAPLYTA, AUSTEDO XR, INGREZZA, COBENFY, ARISTADA, VRAYLAR, REXULTI, HETLIOZ.
Industry payments across NY — which companies pay providers there.
